Related Experiment Video

Updated: Aug 29, 2026

Ultra-Fast Amplicon-Based Next-Generation Sequencing in Non-Squamous Non-Small Cell Lung Cancer
07:59

Ultra-Fast Amplicon-Based Next-Generation Sequencing in Non-Squamous Non-Small Cell Lung Cancer

Published on: September 8, 2023

Locally advanced, unresectable non-small cell lung cancer shift in the treatment paradigm

C P Belani

    Clinical Lung Cancer
    |January 21, 2004
    PubMed
    Abstract

    No abstract available in PubMed .

    More Related Videos

    Thoracoscopic Extended Right Middle Plus Lower Sleeve Lobectomy for Non-Small-Cell Lung Cancer
    11:17

    Thoracoscopic Extended Right Middle Plus Lower Sleeve Lobectomy for Non-Small-Cell Lung Cancer

    Published on: February 27, 2026

    Related Experiment Videos

    Last Updated: Aug 29, 2026

    Ultra-Fast Amplicon-Based Next-Generation Sequencing in Non-Squamous Non-Small Cell Lung Cancer
    07:59

    Ultra-Fast Amplicon-Based Next-Generation Sequencing in Non-Squamous Non-Small Cell Lung Cancer

    Published on: September 8, 2023

    Thoracoscopic Extended Right Middle Plus Lower Sleeve Lobectomy for Non-Small-Cell Lung Cancer
    11:17

    Thoracoscopic Extended Right Middle Plus Lower Sleeve Lobectomy for Non-Small-Cell Lung Cancer

    Published on: February 27, 2026

    Related Concept Videos

    Targeted Cancer Therapies02:57

    Targeted Cancer Therapies

    The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
    There are several types of targeted therapies against specific...
    Treatment Resistent Cancers02:56

    Treatment Resistent Cancers

    Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...

    Articles linked to this work by shared authors, journal, and citation graph.

    A randomized trial of TLR-2 agonist CADI-05 targeting desmocollin-3 for advanced non-small-cell lung cancer.

    Annals of oncology : official journal of the European Society for Medical Oncology·2016

    A multicenter phase II study of cetuximab in combination with chest radiotherapy and consolidation chemotherapy in patients with stage III non-small cell lung cancer.

    Lung cancer (Amsterdam, Netherlands)·2013

    Identifying the target NSCLC patient for maintenance therapy: an analysis from a placebo-controlled, phase III trial of maintenance pemetrexed (H3E-MC-JMEN).

    Annals of oncology : official journal of the European Society for Medical Oncology·2013

    Phase Ib safety and pharmacokinetic study of volociximab, an anti-α5β1 integrin antibody, in combination with carboplatin and paclitaxel in advanced non-small-cell lung cancer.

    Annals of oncology : official journal of the European Society for Medical Oncology·2012

    Differential effect of age on survival in advanced NSCLC in women versus men: analysis of recent Eastern Cooperative Oncology Group (ECOG) studies, with and without bevacizumab.

    Lung cancer (Amsterdam, Netherlands)·2012

    Recent clinical developments and rationale for combining targeted agents in non-small cell lung cancer (NSCLC).

    Cancer treatment reviews·2011

    PINPOINT: Integrating Computer Assisted Detection and Virtual Nodule Clinics for Early Lung Cancer Detection in Routine Practice, A Pilot Study.

    Clinical lung cancer·2026

    Rationale and Study Design of the GUIDANCE trial: A Multicenter Phase II Trial of Maintenance Durvalumab and Olaparib After Standard Fist Line Treatment (Carboplatin/Cisplatin, Etoposide, and Durvalumab) in HRD Positive Extensive Disease (ED) Small-cell Lung Cancer (SCLC) (AIO-TRK-0124/ass).

    Clinical lung cancer·2026

    Using Induction Chemoimmunotherapy as a Bridge to Definitive Local Therapy for Non-Metastatic NSCLC: Real-World Outcomes From a Comprehensive Cancer Center.

    Clinical lung cancer·2026

    Hyperprogression Upon Cemiplimab Alone or With Short Course Chemotherapy in PD-L1 ≥ 50% Non-small Cell Lung Cancer: A Biomarker Guided Multicenter International Phase 2 Trial-HYPERBOLIC Study.

    Clinical lung cancer·2026

    Assessing Guideline-Directed Care in the New Era of Neoadjuvant Therapy in Early-Stage Resectable Non-small Cell Lung Cancer (NSCLC): A Retrospective Review.

    Clinical lung cancer·2026

    Consolidative Hypofractionated Radiotherapy for Oligometastatic Non-Small-Cell Lung Cancer.

    Clinical lung cancer·2026
    See all related articles
    JoVE
    x logofacebook logolinkedin logoyoutube logo
    ABOUT JoVE
    OverviewLeadershipBlogJoVE Help Center
    AUTHORS
    Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
    LIBRARIANS
    TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
    RESEARCH
    JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
    EDUCATION
    JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
    Terms & Conditions of Use
    Privacy Policy
    Policies
    Jove
    Visualize
    Contact Us